REAL-WORLD CHARACTERISTICS AND RISK OF CARDIOVASCULAR EVENTS IN HIGH CARDIOVASCULAR RISK PATIENTS IN FRANCE

被引：0
|
作者：
Desamericq, G. [1 ]
Fagnani, F. [2 ]
Emery, C. [3 ]
Gourmelen, J. [4 ]
Chauny, J. V. [1 ]
Kutikova, L. [5 ]
机构：
[1] Amgen SAS, Value Access & Policy, Boulogne Billancourt, France
[2] Cemka Eval, Direct, Bourg La Reine, France
[3] Cemka Eval, Biostat, Bourg La Reine, France
[4] UVSQ, INSERM, Unite Cohortes Epidemiol Populat, UMS 011, Villejuif, France
[5] Amgen Europe GmbH, Global Hlth Econ, Rotkreuz, Switzerland
来源：
ATHEROSCLEROSIS | 2019年 / 287卷
关键词：
D O I：
10.1016/j.atherosclerosis.2019.06.546
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EAS19-0113
引用
收藏
页码：E180 / E180
页数：1
相关论文
共 50 条
  • [1] Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence
    Toth, Peter P.
    Fazio, Sergio
    Wong, Nathan D.
    Hull, Michael
    Nichols, Gregory A.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (03): : 279 - 289
  • [2] REAL-WORLD STATIN UTILIZATION AMONG PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS: US ANALYSES
    Lin, I
    Sung, J. C.
    Sanchez, R.
    Mallya, U. G.
    Friedman, M.
    Panaccio, M.
    Koren, A.
    Neumann, P. J.
    Menzin, J.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A152 - A152
  • [3] Management of atherosclerosis risk factors for patients at high cardiovascular risk in real-world practice: a multicentre study
    Phrommintikul, Arintaya
    Krittayaphong, Rungroj
    Wongcharoen, Wanwarang
    Yamwong, Sukit
    Boonyaratavej, Smonporn
    Kunjara-Na-Ayudhya, Rapeephon
    Tatsanavivat, Pyatat
    Sritara, Piyamitr
    [J]. SINGAPORE MEDICAL JOURNAL, 2017, 58 (09) : 535 - 542
  • [4] Assessment of cardiovascular events in a real-world high-risk cohort with type 2 diabetes or atheroscleortic cardiovascular disease in Germany
    Verket, M.
    Kossack, N.
    Brandts, J.
    Schoenfelder, T.
    Schuett, K.
    Haeckl, D.
    Marx, N.
    Mueller-Wieland, D.
    [J]. DIABETOLOGIA, 2022, 65 (SUPPL 1) : S449 - S449
  • [5] PCSK9-Inhibitor treatment of cardiovascular high risk patients in a real-world setting
    Kassner, U.
    Hollstein, T.
    Grenkowitz, T.
    Scharnagl, H.
    Maerz, W.
    Steinhagen-Thiessen, E.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 : 1041 - 1041
  • [6] PREDICTORS OF CARDIOVASCULAR EVENTS IN HYPERTENSIVE PATIENTS WITH HIGH CARDIOVASCULAR RISK
    Tasic, I.
    Kostic, S.
    Bastac, D.
    Djordjevic, D.
    Rihter, M.
    Lovic, M.
    Lovic, D.
    Mijalkovic, D.
    [J]. JOURNAL OF HYPERTENSION, 2017, 35 : E98 - E98
  • [7] Predictors of Cardiovascular Events in Hypertensive Patients with High Cardiovascular Risk
    Tasic, Ivan
    Kostic, Svetlana
    Stojanovic, Nikola M.
    Djordjevic, Dragan
    Bogdanovic, Dragan
    Ilic, Marina Deljanin
    Lovic, Milan
    Stoickov, Viktor
    Aleksandric, Srdjan
    [J]. MEDICINA-LITHUANIA, 2020, 56 (04):
  • [8] High risk characteristics in patients with hypertrophic cardiomiyopathy for predicting cardiovascular events
    Keskin, B.
    Arslan, S. A.
    Uzunhasan, I. U.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2481 - 2481
  • [9] Real-world incidence and risk factors of bortezomib-related cardiovascular adverse events in patients with multiple myeloma
    Jang, Bitna
    Jeong, Jonghyun
    Heo, Kyu-Nam
    Koh, Youngil
    Lee, Ju-Yeun
    [J]. BLOOD RESEARCH, 2024, 59 (01)
  • [10] IS ALCOHOL CONSUMPTION ASSOCIATED WITH A LOWER RISK OF CARDIOVASCULAR EVENTS IN PATIENTS TREATED WITH STATINS? AN OBSERVATIONAL REAL-WORLD EXPERIENCE
    Anderson, Jeffrey L.
    Le, Viet T.
    Bair, Tami L.
    Muhlestein, J. Brent
    Knowlton, Kirk U.
    Horne, Benjamin Davies
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1602 - 1602
12345